Document:

<PAGE>   1
                                                                   EXHIBIT 10.29

                           AGILENT TECHNOLOGIES INC.
                                      AND
                                 DIADEXUS INC.

                    DNA MICROARRAY TECHNOLOGY ACCESS PROGRAM

                         MASTER EARLY ACCESS AGREEMENT

<PAGE>   2

                               TABLE OF CONTENTS

<TABLE>
<CAPTION>
                                                                                  Sections
                                                                                  --------
<S>                                                                                <C>
  RECITALS

  DEFINITIONS ......................................................................1
  ORDERING ARRAY PLATFORM PRODUCTS .................................................2
  LICENSE GRANTS....................................................................3

     Licenses to Licensee; Certain Requirements ..................................3.1

     Restrictions on Use .........................................................3.2

     Protection of Agilent Technology, including Trade Secrets ...................3.3

     Return of LP-2, MR-2 Exchange ...............................................3.4

     Intellectual Property Protection/Proprietary Markings .......................3.5

     Ownership....................................................................3.6

  TERM..............................................................................4
  TAXES ............................................................................5
  WARRANTY; REMEDY; DISCLAIMER .....................................................6

     Warranties...................................................................6.1

     Licensee's Acknowledgements and Waiver ......................................6.2

     Warranty only for the Benefit of Licensee ...................................6.3

     Limitations on the Warranties ...............................................6.4

     Affects of Modifying Array Platform Products ................................6.5

  REMEDY FOR A BREACH OF WARRANTY; DISCLAIMERS .....................................7

     Remedy ......................................................................7.1

     Disclaimer of Warranties ....................................................7.2
</TABLE>

<PAGE>   3

<TABLE>
<S>                                                                             <C>

INDEMNIFICATIONS..................................................................8

   Indemnification by Licensee................................................. 8.1

   Agilent's Infringement Indemnification...................................... 8.2

   Limitation of Indemnification to Licensee................................... 8.3

   Entire Liability; No Consequential Damages.................................. 8.4

LIMITATION OF LIABILITY AND ACTIONS ..............................................9

   Limitations on Agilent's Liability ..........................................9.1

   Disclaimers .................................................................9.2

   Limitation of Actions .......................................................9.3

COVENANT NOT TO SUE .............................................................10

CONFIDENTIALITY AND NONDISCLOSURE ...............................................11

   Confidentiality/Non-Disclosure of Agilent Confidential Information..........11.1

   Confidentiality/Non-Disclosure of Licensee Confidential Information.........11.2

   Equitable Relief............................................................11.3

TERMINATION .....................................................................12

   Expiration..................................................................12.1

   Basis for Termination by Agilent ...........................................12.2

   Basis for Termination by Licensee ..........................................12.3

   Disposition of Licensed Items on Termination ...............................12.4

GENERAL..........................................................................13

   Waiver, Amendment or Modification ..........................................13.1

   Notices ....................................................................13.2

</TABLE>

<PAGE>   4
<TABLE>
<S>                                                                                <C>

     Entire Agreement ...........................................................13.3

     Successors And Assigns .................................................... 13.4

     Governing Law; Severability ............................................... 13.5

     Compliance With The Law ................................................... 13.6

     Relationship Of The Parties ............................................... 13.7

     Survival .................................................................. 13.8

     Publication ............................................................... 13.9

     Force Majeure .............................................................13.10

     Counterparts ..............................................................13.11

     Headings ..................................................................13.12

     Tap Order............................................................. Exhibit A

     Customer Feedback Form.................................................Exhibit B
</TABLE>

<PAGE>   5

                            AGILENT TECHNOLOGIES INC.
                    DNA MICROARRAY TECHNOLOGY ACCESS PROGRAM
                          MASTER EARLY ACCESS AGREEMENT

Reference Number: Quote #2000-074

       This DNA Microarray Technology Access Program Master Early Access
Agreement ("Agreement") dated as of this 23rd day of August, 2000, (the
"Effective Date"), is entered into between Agilent Technologies Inc., with
principal offices located at 395 Page Mill Road, Palo A1to, CA 94306 ("Agilent")
and diaDexus Inc., with principal offices located at 3303 Octavius Drive, Santa
Clara CA 95054 ("Licensee").

                                    RECITALS

       WHEREAS: Agilent has an ongoing DNA Microarray Technology Access Program
("TAP") for DNA microarray technology, products, and services and desires to
provide Licensee with, and Licensee desires to obtain, early access to any of
the latest-developed components of TAP "Array Platform Products" (as hereinafter
defined) prior to any commercial release of like products.

       WHEREAS: Early access offers Licensee a competitive advantage, in
addition to which, the potential to influence the direction of Agilent future
product research and development in the area of DNA microarray technology
through direct feedback and input from Licensee regarding the Array Platform
Products. As such, Agilent is willing to grant Licensee and Licensee desires to
acquire rights for early access to the Array Platform Products on the terms and
conditions stated in this Agreement.

       WHEREAS: Agilent desires to obtain data, information and input from
Licensee regarding the performance and use of the Array Platform Products and,
in addition, the priorities of Licensee in the development of future Agilent
products to assist Agilent in its ongoing development of the Array Platform
Products. Such data, information and input from Licensee is intended to help
perfect or improve the product and service performance of the Array Platform
Products.

       WHEREAS: Licensee is willing to assist Agilent in evaluating the Array
Platform Products by supplying data, information and input to Agilent regarding
the performance and use of the Array Platform Products (as provided in Exhibit
B, attached hereto and made a part of this Agreement) and, in addition,
potentially

                                       1
<PAGE>   6

influence the development of future Agilent products in accordance with
Licensee's desires.

       NOW THEREFORE: Licensee is willing to accept the TAP on the terms and
conditions set out herein, and is willing to accept the limited licenses and
other limitations and restrictions set out in this Agreement.

                                    AGREEMENT

       In consideration of the foregoing Recitals and the mutual covenants,
terms, and conditions contained herein, the Parties hereto agree as follows:

1. DEFINITIONS.

Each of the capitalized terms in this Agreement shall have the meaning defined
below. Terms defined in singular form shall include as appropriate the plural
form and vice versa.

       1.1 "Affiliate" means any Entity controlled by, controlling, or under
common control with, a Party hereto and shall include without limitation any
company more than fifty percent (50%) of whose voting stock or participating
profit interest is owned or controlled, directly or indirectly, by a Party, and
any company which owns or controls, directly or indirectly, more than fifty
percent (50%) of the voting stock of a Party.

       1.2 "AGREEMENT" shall mean this Agreement and any Exhibits attached
hereto.

       1.3 "AGILENT FIELD" means the analysis of biological processes in
research and development.

       1.4 "AGILENT KNOW-HOW" means all scientific, technical and engineering
information whatsoever which (i) Agilent (or its predecessor-in-interest) owns
or controls or to which Agilent (or its predecessor-in-interest) has a license
including the right of sublicense as of the Effective Date or during the Term,
(ii) Agilent uses reasonable efforts to protect as a trade secret, (iii) is
incorporated into or used in the design, development, manufacture,
commercialization or use of any Platform Array or Platform Array Enhancement and
(iv) is not publicly known or available and is not the subject of a patent
application.

       1.5 "AGILENT PATENTS" means all patents and patent applications that
relate to the Array Platform Products and that, as of the Effective Date,
Agilent owns, controls, or has a license to, with the right to sublicense, where
(i) patents include, without limitation, any substitutions, extensions,
reissues, renewals, supplementary protection certificates and inventors'
certificates, which have not

                                       2
<PAGE>   7

been held invalid or unenforceable by a non-appealable or non-appealed decision
of a court of competent jurisdiction and (ii) "patent applications" means all
applications filed in any jurisdiction including, without limitation, any
provisionals, divisionals, continuations, and continuations-in-part and that
relate to the Array Platform Products or that cover Inventions or discoveries
that are generated during the Term by Agilent as a result of activities
conducted pursuant to the TAP or as a result of an "Array Platform Product
Enhancement"(as defined in Section 1.8 below).

       1.6 "AGILENT TECHNOLOGY" means Agilent Patents, Agilent Know-How and
Agilent copyrights and trademarks relating to any Array Platform Product, Array
Platform Product Enhancement or portion thereof.

       1.7 "ARRAY PLATFORM PRODUCTS" means the LP-2, MR, Feature Extraction
Software, Custom In Situ Microarrays, hybridization chambers, hybridization
oven, slide holders, products of Technical System Support ("Support Products"),
and Systems Upgrades, including Array Platform Product Enhancements and any
associated protocols for using the foregoing as provided to Licensee by Agilent.

       1.8 "ARRAY PLATFORM PRODUCT ENHANCEMENTS" means enhancements, additions
or refinements to Array Platform Products wherein the use of such enhancements,
additions or refinements in the context of its application to or in connection
with Array Platform Products involves Agilent Technology. "Array Platform
Product Enhancements" are those which have been developed solely by Agilent or
jointly by Agilent and Licensee during the Term (as further described in Section
3.6).

       1.9 "BANKRUPTCY EVENT" means an event or circumstance with respect to a
Party whereby such Party (i) ceases conducting its business in the normal
course, (ii) makes a general assignment for the benefit of its creditors, (iii)
petitions, applies for, suffers or permits, with or without its consent, the
appointment of a custodian, receiver, trustee in bankruptcy or similar officer
for all or any substantial part of its business or assets or (iv) avails itself
or becomes subject to any proceeding under the U.S. Bankruptcy Code or any
similar state, federal or foreign statute relating to bankruptcy, insolvency,
reorganization, receivership, arrangement, adjustment of debts, dissolution or
liquidation, which proceeding is not dismissed within sixty (60) days of
commencement thereof.

       1.10 "COLLABORATOR" means any Third Party engaged with Licensee in a
Collaboration.

       1.11 "COLLABORATION" means a bona fide scientific collaboration between
Licensee and a Third Party under a written contract and research plan in a

                                        3
<PAGE>   8

specified area, in which: (a) such Third Party receives biological materials
and/or proprietary information of Licensee or Licensee receives biological
materials and/or proprietary information of the Third Party; (b) Licensee has
been granted significant proprietary rights for significant intellectual
property generated in the collaboration; (c) the collaboration is within
licensee's normal business model (which model is as of the Effective Date,) and
wherein Licensee's normal business model does not include the provision of
nucleic acid hybridization services or products or database distribution
services or products for Third Parties; (d) Licensee and its collaborator
provide significant scientific input to the collaboration in addition to data,
wherein significant scientific input includes, for example, material input to
experimental design, material contributions to experimental execution and
material data analysis; and (e) the data are used primarily to facilitate
Licensee's research, development, or commercialization of particular molecules,
classes of molecules, or therapeutic areas. A Collaboration shall not in any
event, however, include an arrangement under which a Licensee provides
Microarray Services on a fee-for-service or similar basis, nor shall a
Collaboration include any arrangement by Licensee with a Third Party who engages
in business to provide services similar to Microarray Services, or to provide
analysis of Microarray data.

       1.12 "COMPONENT" means an element, component or constituent of an Array
Platform Product or a device, method, or chemical used in the design,
development, manufacture or use of an Array Platform Product.

       1.13 "CONFIDENTIAL INFORMATION" means any information disclosed by one
Party to the other in connection with activities under this Agreement including,
but not limited to, know how, scientific, technical and engineering information,
reports exchanged between the Parties, marketing and other business plans,
information relating to a Party's products, sales, financial and corporate
affairs, suppliers, customers, employees, or investors, and other comparable
information; provided, that information will be "Confidential Information" only
if it is so identified hereunder or marked as confidential at the time of
disclosure or, if the material is not in written form (e.g., orally disclosed),
it is treated as confidential at the time of disclosure (or there is some
express indication that the oral disclosure was among information intended to be
kept confidential at the time of disclosure); and provided further that
information will not be "Confidential Information" if it is or becomes generally
known or available to the public other than through a prohibited disclosure by a
Party hereto, or if such information becomes known to a Party on a
non-confidential basis from a third party, or if such information is later
publicly made known by the disclosing Party, or if such information was already
known to the receiving Party before the disclosure by the disclosing Party.

     1.14 "CUSTOM IN SITU MICROARRAY" means an In Situ Microarray using
nucleotides provided by Licensee.

                                       4
<PAGE>   9

       1.15 "EFFECTIVE DATE" shall mean the date first set forth above.

       1.16 "ENTITY" means any natural or legal person, partnership, association
or governmental authority.

       1.17 "FEATURE EXTRACTION SOFTWARE" means software that is used by or in
an LP-2 or MR-2 and that is limited to extraction of basic feature identity data
(i.e., association of a particular feature with a particular probe) and
intensity data (i.e., reporting of the signal and noise, background, confidence
and associated statistics) from such LP-2 or MR-2.

       1.18 "INVENTION" means anything that is potentially patentable under the
patent law of the United States (Title 35, U.S. Code Section 101 et seq.).

       1.19 "IN SITU MICROARRAY" means a Microarray in which oligonucleotides or
oligonucleotide analogs are synthesized from individual nucleotides or
nucleotide analogs on a substrate, to be used as probes in research or
development activities.

       1.20 "MICROARRAY" means a substrate-bound spatially ordered collection of
nucleic acid molecules or nucleic acid analogs that can bind specifically to:
(a) nucleic acid molecules; or (b) molecules that can bind nucleic acids, where
the spatially ordered collection of such molecules is configured to allow for
the simultaneous probing of a plurality of specific and unique target molecules
present in a single sample mixture.

       1.21 "MICROARRAY DESIGN SERVICES" means consulting services provided by
Agilent relating to the choice of probe sequences and their arrangement on In
Situ Microarrays.

       1.22 "MICROARRAY SERVICES" means generally, services through the use of
or using Microarrays.

       1.23 "NON-ARRAY PLATFORM JOINT INVENTION" shall have the meaning ascribed
to it in Section 4.4.2 hereof.

       1.24 "PARTY" and "PARTIES" means Agilent and/or Licensee as the context
requires.

       1.25 "SUPPL(Y)(IED)(YING)" means sell, supply, lend, let out on hire,
lease or any other disposal, and in the case of services and databases includes
the provision of access to information.

       1.26 "SYSTEMS UPGRADES" means such upgrades to the Array Platform
Products as Agilent develops and has available for shipping during the term
hereof.

                                        5

<PAGE>   10

       1.27 "TERM" shall have the meaning ascribed thereto in Section 5 hereof.

       1.28 "THIRD PARTY" means any individual or entity other than Licensee,
Agilent or Affiliates of either Party.

2. ORDERING ARRAY PLATFORM PRODUCTS; SERVICES PROVIDED.

       2.1 MASTER AGREEMENT, ONGOING SALES AND SERVICES. This Agreement is a
master agreement under which Licensee enters into a subscription for TAP.
Pursuant to this Agreement, Licensee shall order from Agilent any combination of
the following products, services, and/or support, which altogether or as a
subset make up the Array Platform Products, as identified in items 2.2.1 through
2.2.6 below. The services and support of Sections 2.2.3--2.2.6 (the "Services")
is a subset of the Array Platform Products. Licensee shall order Array Platform
Products by signing and delivering to Agilent an order in a form approved by
Agilent that contains substantially the information set forth in Exhibit "A"
("TAP Order"), for the prices set out therein. Such TAP Order shall not be
binding until accepted by Agilent in writing. Licensee may make further orders
for certain of the individual components of TAP as described in items 2.2.1
through 2.2.3, if available, at the times and for prices as provided in a
supplement to Exhibit A. Agilent's acceptance of any order made by Licensee
under this Agreement shall be subject to all applicable provisions of this
Agreement as well as any additional provisions that may be set forth in the
order. Licensee order configuration and further terms relating to the products
are on contained on Exhibit A.

       2.2 THE ARRAY PLATFORM PRODUCTS.

              2.2.1 SCANNER. If Licensee is ordering a Scanner, the TAP Order
will include one (1) Microarray Scanner (the "LP-2") which is a developmental
prototype DNA scanner that uses two lasers to rapidly read microarrays.
Additional LP-2's may be ordered at the discounted price as Agilent may offer
and set out in Exhibit "A", pursuant to the Terms and Conditions of the TAP
Order. Upon its commercial availability, each ordered LP-2 shall be exchanged
for the commercial released version (the "MR-2") of the LP-2 DNA Scanner.

              2.2.2 CUSTOM IN SITU MICROARRAYS. If Licensee is ordering Custom
In Situ Microarrays, Licensee's TAP Order will specify Custom In Situ
Microarrays, to be delivered in the quantities, at the times and for the prices
provided in Exhibit A. Sequences shall be specified by Licensee and digitally
transmitted to Agilent. Agilent shall prepare the In Situ Microarrays according
to the delivery schedule provided in Exhibit A, provided Agilent receives the
necessary array content information at the appropriate time and such information
is provided in accordance with Agilent's array sequence specifications.
Additional Custom In Situ Microarrays will be available to Licensee according to
a discount schedule

                                       6
<PAGE>   11

attached as Exhibit "A"and pursuant to the Terms and Conditions of the TAP
Order.

              2.2.3 MICROARRAY DESIGN SERVICES. This TAP Order includes the
Microarray Design Services, described in Exhibit "A". Additional Microarray
Design Services will be available to Licensee according to a discount schedule
provided in Exhibit "A", pursuant to the Terms and Conditions of the TAP Order.

              2.2.4 SCIENTIFIC CONSULTING. Each TAP Order includes Scientific
Consulting during the Term.

              2.2.5 TECHNICAL SYSTEM SUPPORT. Each TAP Order includes
installation, training or other services, depending on the particular Array
Platform Products ordered.

              2.2.6 SYSTEMS UPGRADES. Each TAP Order includes the right of
Licensee to receive such upgrades to the Array Platform Products as Agilent
develops and has available for shipping during the Term.

3. LICENSE GRANTS.

       3.1 LICENSES TO LICENSEE; CERTAIN REQUIREMENTS.

              3.1.1 ARRAY PLATFORM PRODUCTS. Subject to the terms and conditions
of this Agreement Agilent hereby grants to Licensee and its Affiliates or
Collaborators under the Agilent Technology, a worldwide non-exclusive,
non-sublicensable, license only for use with the Array Platform Products
delivered to Licensee by Agilent pursuant to Sections 2.2.1, 2.2.2, 2.2.3 and
2.2.6 hereof in accordance with the labels (as described in Section 3.1.2 below)
for, or affixed to, the Array Platform Products.

              3.1.2 LABELS FOR USE OF THE ARRAY PLATFORM PRODUCTS. Labels for
the use of the Array Platform Products shall accompany the delivery of the Array
Platform Products and shall state the following restriction:

                     The use of the Array Platform Products (including, but not
              limited to the LP-2 or MR DNA Microarray Scanner, Custom In Situ
              Microarrays, and any Systems Upgrades) is restricted to internal
              use for research purposes only. Internal use includes use by an
              Affiliate of Licensee and use in a Collaboration.

              3.1.3 INTERNAL USE ONLY. The use of the Array Platform Products
(including, but not limited to the LP-2 or MR-2 DNA Microarray Scanner, Custom
In Situ Microarrays, Microarray Design Services, and any Systems Upgrades) is
restricted to internal use only. Internal use includes use in a Collaboration.

                                       7
<PAGE>   12

        3.2 RESTRICTIONS ON USE. Licensee is authorized to use the Array
Platform Products only under the license provided and in accordance with Section
3.1 and the rest of this Agreement. Licensee shall not use the Array Platform
Products in any manner not expressly authorized by the Agreement. Licensee shall
not (i) rent, sell, assign, lease, share, sublicense, or otherwise transfer or
dispose of the Array Platform Products or any portion thereof, or use the Array
Platform Products in any manner not expressly authorized by this Agreement; (ii)
derive or attempt to derive the source code, source files, microarray designs or
structure of all or any portion of the Array Platform Products except Joint
Enhancement(s) by reverse engineering, disassembly, decompilation, or any other
means; (iii) copy, translate, port, modify, make derivative works of the Array
Platform Products, or file patent applications based on the Array Platform
Products that incorporate Agilent Technology except Joint Enhancement(s), except
to the extent (if any) expressly authorized by this Agreement; or (iv) use the
Array Platform Products to construct commercial databases or provide
microarray-derived data (other than Licensee's probe design data) or services to
Third Parties (other than Collaborators) without securing an additional license
from Oxford Gene Technology, Ltd. specifically permitting such activities.

        3.3 PROTECTION of AGILENT TECHNOLOGY, INCLUDING TRADE SECRETS. Licensee
acknowledges and agrees that the Array Platform Products and portions thereof
are based on Agilent Technology including but not limited to Agilent Know-How
and Agilent Patents. Licensee agrees to use the Array Platform Products, Agilent
Technology, and any portion thereof, only in accordance with the terms of the
Agreement. Licensee agrees that it shall not use the Array Platform Products,
Agilent Technology or any portion thereof, in developing similar or competitive
products to the licensed items. For example, Licensee shall not use
Agilent-provided probes, probe sets or microarray designs to develop non-Agilent
probes, probe sets, in situ microarrays or microarray designs. Notwithstanding
any other rights and remedies Agilent may have, and providing for any
improvements to Array Platform Technology pursuant to Section 3.6.5, Licensee
agrees that in the event that the Array Platform Products, Agilent Technology,
and any portion thereof is used by Licensee in the development of similar or
competitive products or services to the Array Platform Products, or in achieving
intellectual property rights including but not limited to patent, copyright,
trade secret or trademark protection covering similar or competitive products or
services to the Array Platform Products, then Licensee shall grant to Agilent a
perpetual, worldwide, non-exclusive, royalty freely sub-licensable license,
under such intellectual property rights, to manufacture, have manufactured, use,
Supply, offer for Supply, or import and export, any products or services covered
by such intellectual property rights.

        3.4 RETURN OF LP-2, MR-2 EXCHANGE. Upon the commercial availability of
the MR-2, Licensee shall return to Agilent all LP-2(s) originally delivered to
Licensee, in exchange for MR-2(s) at no added cost. Notwithstanding the
foregoing, if Licensee terminates the Agreement before the end of the Term and
Licensee has

                                       8
<PAGE>   13

not fully paid for the Array Platform Products as specified in Exhibit A,
Licensee shall immediately return to Agilent without any exchange all LP-2(s)
and MR-2(s).

       3.5 INTELLECTUAL PROPERTY PROTECTION/PROPRIETARY MARKINGS. The Array
Platform Products contain material that is protected by United States copyright
law and trade secret law, and by international treaty provisions. All rights not
expressly granted to Licensee under this Agreement are expressly reserved by
Agilent (or its licensor or supplier). Licensee agrees not to remove or destroy
any proprietary markings or confidential legends placed upon or contained within
the Array Platform Products, any related documentation, or any other related
materials.

       3.6 OWNERSHIP.

              3.6.1 ARRAY PLATFORM PRODUCTS. Agilent shall own all copyrights,
patents, trade secrets, trademarks, service marks, tradenames, moral rights and
other intellectual property and proprietary rights in the Array Platform
Products and Array Platform Product Enhancements. Array Platform Product
Enhancements conceived or reduced to practice during the Term solely by Agilent
or jointly by Agilent and Licensee shall be owned by Agilent. Licensee shall
cooperate with Agilent in providing any necessary executed assignments,
agreements and/or documentation to effect the transfer of any Licensee ownership
of such jointly developed Array Platform Product Enhancements to Agilent.
Licensee shall also reasonably cooperate with Agilent, if necessary, in the
filing, prosecution and maintenance of any patent applications and the issuance
and maintenance of any resulting patents of such jointly developed Array
Platform Product Enhancements.

              3.6.2 NON-ARRAY PLATFORM JOINT INVENTION. All rights and title to
joint inventions of Licensee and Agilent excluding any Array Platform Product
Enhancements ("Non-Array Platform Joint Inventions"), whether patentable or
copyrightable or not, will belong jointly to Licensee and Agilent and will be
subject to the terms and conditions of this Agreement. Each Party will have the
right to independently practice the Non-Array Platform Joint Inventions, without
accounting to the other Party, only to the extent that the practice of the
Non-Array Platform Joint Inventions by Licensee does not require rights under
any other intellectual property rights owned by, either partially or wholly, or
licensed to Agilent, and that practice of the Non-Array Platform Joint
Inventions by Agilent does not require rights under any other Intellectual
Property Rights owned by, either partially or wholly, or licensed to Licensee.

              3.6.3 RIGHT TO BRING ACTION FOR NON-ARRAY PLATFORM JOINT
INVENTIONS. Each Party will have the right but not the obligation to bring, at
its own expense, an infringement action against any third party under its
interest in Non-Array Platform Joint Inventions, subject to the same limitations
set forth above with respect to the practice of the Non-Array Platform Joint
Inventions by

                                       9
<PAGE>   14

Agilent or Licensee. The Parties will assist one another and cooperate in any
such litigation at the other's reasonable request, and, if a Party is necessary
in order to institute or maintain an infringement suit by the other Party as
defined by law, that Party agrees to be joined in the suit. Licensee and Agilent
will jointly have the right, using in-house or outside legal counsel selected by
both Parties, to prepare, file, prosecute, maintain and extend patent
applications for Non-Array Platform Joint Inventions in countries of the Party's
choosing.

              3.6.4 FILING PATENT APPLICATIONS FOR NON-ARRAY PLATFORM JOINT
INVENTIONS. Where only one Party desires to file a patent application ("Filing
Party") for a Non-Array Platform Invention in one or more countries, then such
Filing Party will thereafter have the right, at its sole expense, to prepare,
file, prosecute, and maintain the applications in its own name in the one or
more countries. The other Party will, at its own expense, assign said patent
applications to the Filing Party and provide reasonable assistance to the Filing
Party to facilitate the filing and prosecution of all the patent applications
that the other Party has elected not to pursue, and the other Party will execute
all documents deemed necessary or desirable therefor. The Filing Party will
provide to the other Party a royalty-free non-exclusive license, with right to
sublicense, under all the patent applications that the other Party has elected
not to pursue and the Filing Party has elected to pursue under this Section 3.6.
Licensee and Agilent will each hold all information it presently knows or
acquires under this Section 3.6 as Confidential Information in accordance with
Section 11.

              3.6.5 LICENSEE DEVELOPED PLATFORM IMPROVEMENT. Any improvements to
Array Platform Products conceived or reduced to practice by Licensee during the
Term arising from any knowledge or use of the Array Platform Products without
contribution by Agilent ("Licensee Inventions") shall be owned by Licensee.
Licensee hereby grants to Agilent (and Affiliates) an option (the "Option") for
a period of twelve (12) months from the date of disclosure by Licensee ("Option
Period") to license (and to sublicense to Agilent's customers) to make, have
made, use, sell, have sold, offer to sell, and import Licensee Inventions and to
perform and practice products and services of the Licensee Inventions, not
including Licensee Inventions directed to probe selection methods or algorithms,
wherein the use of such Licensee Inventions in the context of their application
to Array Platform Products will also involve the use of Array Platform Products
that incorporate Agilent Technology, on a world-wide, non-exclusive basis on
reasonable commercial terms. Licensee is under no duty to disclose Licensee
Inventions to Agilent. In the event Licensee does make such disclosure (other
than disclosure of Licensee probe sequences for manufacture of Custom In Situ
Microarrays) or Licensee Inventions become publicly known, Agilent may negotiate
within the Option Period such license and incorporate such improvements into its
Array Platform Products unless Licensee developed such Licensee Invention
entirely independent of any of the Array Platform Products. Any conveyance of
Licensee Inventions to Third Parties shall be subject to the Option.

                                       10
<PAGE>   15

              3.6.6 CONFIDENTIALITY OF LICENSEE'S PROBES. Agilent shall keep all
information provided by Licensee related to Licensee-furnished probe sequences
and layouts in strict confidence, in accordance with the provisions of Section
11.2 hereof. Such information shall be segregated and isolated from Agilent's
own probe and microarray design efforts and used only for the design of
Licensee's Custom In Situ Microarrays. However, Licensee understands and
acknowledges that Agilent, its affiliates and collaborators are also involved in
probe design efforts and may independently design similar or identical probes.

4. TERM.

The Term of this Agreement shall commence upon the Effective Date and shall
expire one (1) year from the Effective Date, or (b) on the date this Agreement
is terminated pursuant to Article 12 hereof, whichever date is earlier;
provided, however, that the Licensee may continue to participate under the terms
of this Agreement subject solely to Agilent's prior approval, which approval may
be withheld at Agilent's sole discretion. All licenses granted hereunder, and
Licensee's subscription to the TAP, shall, unless sooner terminated in
accordance with the provisions of this Agreement, continue until expiration of
the Term, and shall lapse and expire upon expiration of the Term.

5. TAXES.

Licensee shall be responsible for and shall pay all sales, use, excise, personal
property, and other taxes, fees and charges whatsoever ("Taxes") imposed by any
governmental authority relating to, or arising out of, this Agreement or any of
the transactions contemplated hereby, exclusive of Taxes based on or measured by
Agilent's net income, unless Licensee is exempt from the payment of such Taxes
and provides Agilent with evidence of such exemption prior to execution of this
Agreement. In the event Agilent pays any such Taxes, Licensee shall reimburse
Agilent within thirty (30) days after Agilent's written demand.

6. WARRANTIES: LIMITATIONS ON WARRANTIES.

       6.1 WARRANTIES. Agilent hereby warrants the following to Licensee: (a)
that the LP-2 and any Systems Upgrades to the LP-2 shall for one (1) year from
the date of installation be free from defects in material or workmanship that
substantially impair its performance; (b) that the MR and any Systems Upgrades
to the MR shall for one (1) year from the date of installation be free from
defects in material or workmanship; (c) that the Custom In Situ Microarrays will
operate in substantial conformance with the applicable documentation (if any)
during the

                                       11
<PAGE>   16

period expiring ninety (90) days after delivery to Licensee; and (d) that
Technical System Support shall be performed in accordance with any established
professional standards for such services in Agilent's industry, which warranty
as to such services shall expire ninety (90) days after the date they are
performed. All warranty claims not made in a written form and subsequently
received by Agilent within the applicable warranty period identified in the
immediately preceding sentence shall be deemed waived.

       6.2 LICENSEE'S ACKNOWLEDGEMENTS AND WAIVER. Licensee acknowledges and
agrees that (a) the Array Platform Products shall only comply and perform in
accordance with the standards given in the specifications provided for such
Array Platform Products; (b) one significant purpose of this Agreement is to
provide for the Array Platform Products to be evaluated; and (c) Licensee shall
inform those of its employees involved in using the Array Platform Products
about the evaluation aspects of this Agreement. NOTWITHSTANDING ANYTHING TO THE
CONTRARY, ALL FOREGOING WARRANTIES ARE VOID IF LICENSEE DOES NOT FOLLOW AGILENT-
RECOMMENDED PROTOCOLS AND PROCEDURES. MOREOVER, IT IS EXPRESSLY AGREED THAT THE
WARRANTIES IN THIS ARTICLE 6 SHALL BE IN LIEU OF ALL WARRANTIES OF FITNESS AND
IN LIEU OF THE WARRANTY OF MERCHANTABILITY.

       6.3 WARRANTY ONLY FOR THE BENEFIT OF LICENSEE. The foregoing warranties
are solely for the benefit of Licensee, and Licensee shall have no authority to
extend such warranties to any other Entity without Agilent's prior written
consent.

       6.4 LIMITATIONS ON THE WARRANTIES. Notwithstanding Section 6.1 above, the
warranty provisions shall not apply to, and Agilent shall not be responsible
for, any defects caused by or resulting from (i) improper installation or use of
the Array Platform Products by Licensee, its employees or its agents, (ii)
failure by Licensee or its employees or agents to observe any instructions of
Agilent or its representatives, (iii) the negligent acts or omissions of
Licensee or its employees or agents, (iv) unauthorized alterations, adjustments
or modifications by Licensee, its employees or agents, to any of the Array
Platform Technology, (v) failure or malfunctioning of software, hardware, or
other equipment or facilities not delivered or licensed to Licensee by Agilent,
(vi) abuse or misuse of the Array Platform Products, or any damage thereto after
the date of delivery to Licensee, or (vii) failure of Licensee to comply with
Agilent recommended Systems Upgrades without the written waiver of Agilent.

       6.5 AFFECTS OF MODIFYING ARRAY PLATFORM PRODUCTS. Any modification,
adjustment or alteration of the Array Platform Products by Licensee or any other
unauthorized Entity, or failure by Licensee to implement any Systems Upgrades to
the Array Platform Products as supplied by Agilent, shall void Agilent's support
obligations hereunder, and Agilent's warranty obligations under this Article 6,

                                       12
<PAGE>   17

unless Licensee has obtained prior written authorization from Agilent permitting
such modification, adjustment, alteration, or failure to implement.

7. REMEDY FOR A BREACH OF WARRANTY: DISCLAIMERS.

       7.1 REMEDY. In the event of a breach of any of the limited warranties set
forth in Section 6.1 as to which Agilent is notified in writing during the
applicable warranty period, Agilent shall, at its sole option and expense, and
as its exclusive obligation and Licensee's exclusive remedy, repair or have
repaired the defective portion of any of the Array Platform Product or furnish a
substantially conforming replacement, or re-perform the defective Technical
System Support, within a reasonable period after Licensee has notified Agilent
in writing and proved that a breach of warranty has occurred. The exclusive
remedy set forth in this Section 7.1 shall not be deemed to have failed of its
essential purpose so long as Agilent is willing and able to repair (or have
repaired) or replace the defective portions of the Array Platform Products, or
to re-perform defective Technical System Support, within a reasonable time after
Licensee proves to Agilent that a defect covered by warranty has occurred.
Agilent shall have fully performed its remedy obligations set forth in this
Section 7.1 providing that such repair or replacement of the defective portions
of the Array Platform Product(s) or such re-performance of the defective
Technical System Support, as applicable, meets the standards and controls
established as benchmarks for performance of the Array Platform Products and
Technical System Support as provided in their accompanying documentation.

       7.2 DISCLAIMER OF WARRANTIES. EXCEPT AS SPECIFICALLY PROVIDED IN THIS
ARTICLE 7, THE ARRAY PLATFORM PRODUCTS AND THE TECHNICAL SYSTEM SUPPORT ARE
PROVIDED TO LICENSEE "AS IS", WITH ALL FAULTS, AND WITHOUT WARRANTY OF ANY KIND.
EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN SECTION 6.1, AGILENT EXPLICITLY
DISCLAIMS ALL WARRANTIES, EXPRESS AND IMPLIED, INCLUDING, BUT NOT LIMITED TO,
THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.
AGILENT DOES NOT WARRANT TITLE, NOR DOES IT WARRANT THAT THE CUSTOM IN SITU
MICROARRAYS OR ANY ARRAY PLATFORM PRODUCTS--WHERE SUCH ARRAY PLATFORM PRODUCTS
OR IN SITU MICROARRAYS WOULD NOT INFRINGE BUT FOR LICENSEE'S INPUT OR ADDITIONS
THERETO--WILL BE DELIVERED FREE OF THE CLAIMS OF THIRD PERSONS BY WAY OF
INFRINGEMENT OR THE LIKE. AGILENT DOES NOT WARRANT THAT THE ARRAY PLATFORM
PRODUCTS, THE TECHNICAL SYSTEM SUPPORT, OR ANY PORTION OF THE FOREGOING, WILL
MEET LICENSEE'S REQUIREMENTS OR THAT THE OPERATION OF THE ARRAY PLATFORM
PRODUCTS WILL BE UNINTERRUPTED OR ERROR-FREE, OR THAT DEFECTS IN THE ARRAY
PLATFORM PRODUCTS OR THE TECHNICAL SYSTEM SUPPORT WILL BE CORRECTED. LICENSEE
EXPRESSLY AGREES THAT USE OF THE ARRAY PLATFORM PRODUCTS IS AT LICENSEE'S SOLE

                                       13
<PAGE>   18

RISK. AGILENT DOES NOT WARRANT OR MAKE ANY REPRESENTATION REGARDING THE USE OR
THE RESULTS OF THE USE OF THE ARRAY PLATFORM PRODUCTS OR RELATED DOCUMENTATION
BEYOND THE WARRANTIES SPECIFICALLY PROVIDED IN THE ABOVE ARTICLE 6, IN TERMS OF
THEIR CORRECTNESS, ACCURACY, QUALITY, COMPATIBILITY, CURRENTNESS, RELIABILITY,
APPROPRIATENESS FOR A PARTICULAR TASK OR APPLICATION, OR OTHERWISE. NO ORAL OR
WRITTEN INFORMATION OR ADVICE GIVEN BY AGILENT OR AGILENT'S AUTHORIZED
REPRESENTATIVES SHALL CREATE A WARRANTY OR IN ANY WAY INCREASE THE SCOPE OF THE
LIMITED WARRANTIES SET FORTH IN SECTION 6.1.

8. INDEMNIFICATIONS.

       8.1 INDEMNIFICATIONS BY LICENSEE.

              8.1.1 GENERAL INDEMNIFICATION. Subject to Agilent's performance of
its obligations under Section 6.1, except for the subject matter covered by
Agilent's obligations Section 8.2 as limited by Sections 8.4 and 8.5, Licensee
shall protect, defend and indemnify and hold harmless Agilent, its officers,
directors, shareholders, employees, agents, successors and assigns ("Agilent
Indemnitees") from any and all claims, losses, deficiencies, damages,
liabilities, costs, and expenses (including but not limited to reasonable
attorneys' fees and all related costs and expenses) incurred by Agilent
Indemnitees as a result of any claim, complaint, suit, proceeding, cause of
action, judgment or adjudication against Agilent Indemnitees related to or
arising from Licensee's use of the Array Platform Products outside their
intended use.

              8.1.2 INFRINGEMENT INDEMNIFICATION. Licensee shall fully
indemnify, defend, protect and hold harmless Agilent Indemnitees from and
against, third party infringement claims against Agilent Indemnitees asserting
Licensee's, its Affiliate's or Collaborator's use of Custom In Situ Microarrays
where such claims assert: 1) intellectual property rights in specific nucleic
acid sequences, including, without limitation, sequences of the probes attached
to the Custom In Situ Microarrays which sequences were placed on such arrays at
Licensee's, its Affiliate's or Collaborator's request, subsets or supersets
thereof, and complementary sequences; 2) intellectual property rights covering
any aspect of experimentation methodology used by Licensee, its Affiliate or
Collaborator to create samples to use with microarrays, or covering any aspect
of sample preparation in creation by Licensee, its Affiliate or Collaborator of
target(s) for hybridization with the microarrays (excluding Agilent-approved dye
labeling protocols); 3) use by Licensee, its Affiliate or Collaborator of the
TAP technology, products and/or services, in combination with any products or
facilities that are not authorized or approved by Agilent; 4) misuse,
unauthorized modifications, adjustments or alterations made or used by or under
the direction of Licensee, its

                                       14
<PAGE>   19

Affiliate or Collaborator or failure of Licensee, its Affiliate or Collaborator
to implement improvements or upgrades of the TAP technology and/or products as
instructed by Agilent.

       8.2 AGILENT'S INFRINGEMENT INDEMNIFICATION. Agilent shall indemnify
Licensee, its officers, directors, shareholders, employees, agents, successors
and assigns ("Licensee Indemnitees") for third party infringement against
Licensee Indemnitees asserting: 1) use of the LP-2 or MR-2 in accordance with
Agilent's recommended methods, procedures and upgrades; 2) Array Platform
Products as an article of manufacture independent of the sequences thereon; 3)
algorithms used in the design of probes in the Microarray Design Services; 4)
methodology and reagents used in preparation of samples for hybridization to
Custom In Situ Microarrays, if such use is in accordance with Agilent's
recommended methods, protocols, upgrades, reagents and suppliers, except that
this obligation to defend shall not extend to Licensee's, Affiliate,
Collaborator or Licensee Indemnitees willful use of any of the above Agilent
technology, products or services after Licensee's receipt of notice of such
infringement (unless and until Agilent provides Licensee additional reasonable
assurances in writing that such conduct does not infringe of any valid claims of
the noticed patent; and 5) any personal injury arising from the Microarray
Design Services or use of TAP. In the event that any of the products or services
of TAP become the subject of a claim of infringement, Agilent may at its
option, procure third party rights to continue use of any TAP technology,
product or service, replace or modify any of the foregoing, or, only if neither
of the two other options are available terminate the Agreement and refund to
Licensee a pro rata amount of the amounts paid by Licensee hereunder, calculated
based on a five-year straight-line depreciation basis for equipment that may no
longer be used and/or with respect to the In Situ Microarrays, amounts paid by
Licensee for the Custom In Situ Arrays in already firmly ordered by the
termination date or in inventory in an amount that constitutes the remaining
shelf-life of such arrays

       8.3 GENERAL PROVISIONS. The obligations of each party under this Section
8 shall be contingent upon: (i) the indemnified party providing prompt notice to
the indemnifying party of each such action or claim; (ii) the indemnifying party
retaining exclusive control over the action or claim, including selection of
counsel; (iii) the indemnified party provides all assistance reasonably
requested by the indemnifying party, at the expense of the indemnifying party;
(iv) the indemnified party does not settle or enter into negotiations to settle
the action or claim; and (v) the indemnifying party does not settle any such
action or claim that would materially affect the indemnified party without the
indemnified party's prior consent, which consent not to be unreasonably withheld
or delayed.

       8.4 LIMITATION OF INDEMNIFICATION TO LICENSEE. Agilent Indemnitees assume
no liability or indemnity obligation to Licensee beyond that which is provided
in Section 8.2, for claims of infringement based in whole or in part upon the
Array Platform Products. The foregoing indemnification contained in Section

                                       15
<PAGE>   20

8.2 above, for claims asserted against Licensee arising out of or as a result of
any claim of property infringement, including but not limited to any claim based
on patents, know-how or trade secrets of Third Parties, do not include any
claims whatsoever for any liability based on or arising from discoveries or
inventions whether process, art, method, machinery, manufacture, composition of
matter or material, including new uses of any of the foregoing, or any
improvements thereof (collectively, "Discoveries") developed in whole or in part
through the use of, or with the assistance of any Agilent technology, product or
service provided under the Agreement in the form furnished, or as subsequently
modified by Agilent, and do not include any claims for actual or consequential
damages, claims to revenue streams, attorneys' fees or other costs for defending
against such claims based on or arising from such Discoveries, or monies or
other consideration paid in settlement of such claims based on or arising from
such Discoveries. The above Sections 8.2 and 8.3 state Agilent's entire
liability and obligation, and the exclusive remedy of Licensee with respect to
infringement of third party intellectual property rights.

       8.5 ENTIRE LIABILITY; NO CONSEQUENTIAL DAMAGES. THE FOREGOING PROVISIONS
OF THIS ARTICLE 8 PROVIDES FOR THE ENTIRE LIABILITY AND OBLIGATION ON THE PART
OF AGILENT OR AGILENT INDEMNITEES, AND LICENSEE HAS NO OTHER REMEDY, WITH
RESPECT TO ANY INFRINGEMENT OR ALLEGED INFRINGEMENT OF INTELLECTUAL PROPERTY
RIGHTS BY THE ARRAY PLATFORM PRODUCTS, TECHNICAL SYSTEM SUPPORT, SYSTEM
UPGRADES, MICROARRAY DESIGN SERVICES, OR MICROARRAY SERVICES, OR OTHERWISE IN
CONNECTION WITH THIS AGREEMENT.

9. LIMITATION OF LIABILITY AND ACTIONS.

       9.1 LIMITATIONS ON AGILENT'S LIABILITY. Agilent's liability with respect
to the Array Platform Products and all other goods, services, software or
technology sold and/or licensed to Licensee shall be limited to the express
warranty and related remedy provisions set forth in Section 6.1 and 8.2.
Furthermore, Agilent shall not be responsible for use of the Licensed items
herein if not operated in a manner recommended in any related documentation,
including but not limited to recommended Systems Upgrades; nor shall Agilent be
responsible for any non-compliance by Licensee with applicable foreign, federal,
state or local laws or regulations, or failure by Licensee to use audit controls
or back-up and security procedures. Agilent shall not be responsible for any
failure by Licensee to use due care in the use and validation of the results
produced by the Array Platform Products.

       9.2 LIMITATION OF LIABILITY AND DISCLAIMER. Agilent Indemnitees shall
have no liability, beyond that which is set forth in Sections 8.2, as limited by
8.4 above, with respect to infringement. EXCEPT FOR ITS OBLIGATIONS UNDER
SECTIONS 8.2, NEITHER PARTY SHALL BE SUBJECT TO AND DISCLAIMS:

                                       16
<PAGE>   21

(A) ANY OTHER OBLIGATIONS OR LIABILITIES WHATSOEVER ARISING OUT OF OR IN
CONNECTION WITH THIS AGREEMENT OR ANY OF THE TRANSACTIONS CONTEMPLATED HEREBY,
WHETHER FOR BREACH OF CONTRACT OR WARRANTY OR OTHERWISE; (B) ANY OBLIGATIONS
WHATSOEVER ARISING OUT OF TORT CLAIMS (INCLUDING NEGLIGENCE OR STRICT LIABILITY)
OR ARISING UNDER ANY OTHER THEORIES OF LAW WITH RESPECT TO PRODUCTS, SOFTWARE OR
TECHNOLOGY SOLD OR LICENSED, OR SERVICES RENDERED, BY AGILENT OR LICENSEE, ITS
EMPLOYEES OR AGENTS, OR ANY UNDERTAKINGS, ACTS OR OMISSIONS RELATING THERETO;
AND (C) ANY INDIRECT OR PUNITIVE DAMAGES WHATSOEVER, EVEN IF SUCH PARTY HAS
BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. WITHOUT LIMITING THE GENERALITY
OF THE FOREGOING, AND EXCEPT FOR ITS OBLIGATIONS UNDER SECTIONS 8.2, AGILENT
SPECIFICALLY DISCLAIM ANY LIABILITY FOR PENALTIES (INCLUDING WITHOUT LIMITATION
ADMINISTRATIVE PENALTIES); SPECIAL, EXEMPLARY OR PUNITIVE DAMAGES; DAMAGES FOR
LOST PROFITS OR REVENUES; DAMAGES FOR LOSS OF BUSINESS, LOSS OF GOODWILL OR
BUSINESS REPUTATION, OR LOSS OF DATA OR BUSINESS INFORMATION; LOSS OF USE OF
HARDWARE, SOFTWARE, EQUIPMENT OR FACILITIES; DOWNTIME; SHUTDOWN OR SLOWDOWN
COSTS; COST OF CAPITAL; COST OF SUBSTITUTE HARDWARE, SOFTWARE, EQUIPMENT,
FACILITIES, SERVICES OR ARRAYS; OR FOR ANY OTHER TYPES OF ECONOMIC LOSS, OR FOR
CLAIMS BY ANY OF LICENSEE'S CUSTOMERS OR ANY OTHER ENTITY FOR ANY OF THE
FOREGOING THE PARTIES EXPRESSLY AGREE THAT THE FOREGOING EXCLUSION OF INDIRECT
DAMAGES AND DISCLAIMER OF LIABILITY APPLIES IRRESPECTIVE OF WHETHER ANY OR ALL
OF THE WARRANTIES SET FORTH IN SECTION 7 ARE FOUND TO HAVE FAILED OF THEIR
ESSENTIAL PURPOSE. IN NO EVENT SHALL AGILENT BE LIABLE FOR LICENSEE'S MISUSE OR
IMPROPER USE OF TAP AND ARRAY PLATFORM PRODUCTS.

       9.3 LIMITATION OF ACTIONS. No action, regardless of form, arising out of
any of the transactions contemplated by this first Agreement may be brought by
Licensee more than two (2) years after the date on which such cause of action
first accrued.

10. COVENANT NOT TO SUE.

Licensee agrees not to sue Agilent or Agilent's Customers ("Covered Parties"),
under Licensee patents claiming nucleic acid sequence inventions conceived by
Licensee prior to or during the Term of this Agreement ("Licensee Nucleic Acid
Patents"), for such Covered Party's use, marketing, or sale of microarrays that
include nucleic acid sequences claimed in Licensee Nucleic Acid Patents, solely
for discovery research purposes excluding human diagnostics but including the
creation of expression or genotyping databases to provide data to third parties
("Covenant

                                       17
<PAGE>   22

Field") provided that such sequences were obtained or developed by the other
without breach of any confidentiality provisions of this contract. No license is
granted to Agilent under any Licensee patents. This covenant not to sue does not
extend to any use, marketing, or sales activities by Covered Parties outside the
Covenant Field, or to any Licensee patents other than Licensee Nucleic Acid
Patents. This covenant not to sue shall terminate upon the earlier of: (i)
Agilent enters into any agreement with a third party for the development,
manufacture, or sale of microarrays for use in the Covenant Field excluding use
for platform development, that does not include a substantially similar covenant
not to sue; or (ii) upon the last to expire Licensee Nucleic Acid Patents. For
the purposes of this covenant "platform development" means the development of
nucleic acid measurement systems independent of the use of such systems to
measure biological processes.

11. CONFIDENTIALITY AND NON-DISCLOSURE.

       11.1 CONFIDENTIALITY/NON-DISCLOSURE OF AGILENT CONFIDENTIAL INFORMATION.
Licensee hereby agrees that: (a) the Agilent Technology, including but not
limited to any Agilent-provided sequences, microarray design services,
microarray designs, probes or probe designs, any Array Platform Product, Array
Platform Product Enhancement and any Confidential Information of Agilent
(including without limitation Agilent's proprietary information relating to any
microarray probe, sequence or layout), is and shall be treated as the
Confidential Information of Agilent ("Agilent Confidential Information"); (b)
Licensee shall exercise at least the same degree of care to safeguard the
confidentiality of Agilent's Confidential Information (including without
limitation the Agilent Technology) as Licensee would exercise to safeguard
Licensee's most confidential property (but in no event less than a reasonable
degree of care); and (c) neither Agilent's Confidential Information nor any part
thereof, including but not limited to any related documentation, shall be
duplicated by Licensee or its employees or agents (except for normal security
backup purposes) or in any way disclosed by Licensee or its employees or agents
to Third Parties or other Entities, in whole or in part, without the prior
written permission of Agilent, nor may any of Agilent's Confidential Information
be used by Licensee or its employees or agents, except as authorized by this
Agreement. Such prohibition on disclosures shall not apply to disclosures by
Licensee to its employees, provided such disclosures are reasonably necessary to
Licensee's use of the Agilent's Confidential Information as authorized
hereunder, and provided further that Licensee shall ensure that the Agilent
Confidential Information is not duplicated, disclosed or used by such employees
in contravention of this Agreement, and be responsible for any unauthorized
duplication, disclosure or use by said employees. It is expressly understood and
agreed that the obligations of this Section shall survive the expiration or
termination of this Agreement or any provision hereof.

                                       18
<PAGE>   23

       11.2 CONFIDENTIALITY/NON-DISCLOSURE OF LICENSEE CONFIDENTIAL INFORMATION.
Agilent hereby agrees that the Licensee's Confidential Information shall
include, but not be limited to Licensee's proprietary nucleotides, targets
identified by Licensee, materials, data, information, designs, and Confidential
Information ("Licensee Confidential Information") is and shall be treated as the
Confidential Information of Licensee, and that: (a) Agilent shall exercise at
least the same degree of care to safeguard the confidentiality of Licensee's
Confidential Information (including without limitation the Licensee's
proprietary information relating to any microarray probe, sequence or layout) as
Agilent would exercise to safeguard Agilent's most confidential property (but in
no event less than a reasonable degree of care); and (b) neither Licensee's
Confidential Information nor any part thereof, including but not limited to any
related documentation, shall be duplicated by Agilent or its employees or agents
(except for normal security backup purposes) or in any way disclosed by Agilent
or its employees or agents to Third Parties or other Entities, in whole or in
part, without the prior written permission of Licensee, nor may any of
Licensee's Confidential Information be used by Agilent or its employees or
agents, except as authorized by this Agreement. Such prohibition on disclosures
shall not apply to disclosures by Agilent to its employees, provided such
disclosures are reasonably necessary to Agilent's use of the Licensee's
Confidential Information as authorized hereunder, and provided further that
Agilent shall ensure that Licensee's Confidential Information is not duplicated,
disclosed or used by such employees in contravention of this Agreement, and be
responsible for any unauthorized duplication, disclosure or use by said
employees. It is expressly understood and agreed that the obligations of this
Section shall survive the expiration or termination of this Agreement or any
provision hereof.

       11.3 EQUITABLE RELIEF. The Parties acknowledge that any use or disclosure
of the other Party's Confidential Information other than as specifically
authorized in this Agreement or other written agreements between Agilent and
Licensee may result in irreparable injury and damage to other Party.
Accordingly, the Parties hereby agree that, in the event of use or disclosure of
the other Party's Confidential Information other than as specifically authorized
in this Agreement or in other written agreements between the Parties, the other
Party shall be entitled to seek and obtain equitable relief from any appropriate
judicial body.

12. TERMINATION.

       12.1 EXPIRATION. This Agreement shall expire one (1) year from the
Effective Date unless it is earlier terminated pursuant to this Article 12.

       12.2 BASIS FOR TERMINATION BY AGILENT. Agilent shall have the right to
terminate this Agreement and all licenses granted hereunder, immediately upon
giving of written notice by Agilent and without further obligation or liability
to Licensee, if (i) Licensee is delinquent in making payment of any sum due
under this Agreement or any order accepted by Agilent pursuant to Article 2
hereof and

                                       19
<PAGE>   24

continues to be delinquent for a period of seven (7) calendar days after the
date on which such payment was due, and fails to make such payment within thirty
(30) days after receipt of notice to make such payment, or (ii) Licensee commits
any other material breach of this Agreement and fails to remedy such breach
within ten (10) calendar days after receipt of written notice from Agilent of
such breach, or (iii) a Force Majeure event (as defined in Section 13.10) occurs
that prevents either Party from performing any of its material obligations
hereunder and such event continues for at least thirty (30) consecutive calendar
days, or (iv) a Bankruptcy Event occurs with respect to Licensee, or (v) Agilent
is enjoined by any Entity from selling and/or licensing all or any part of the
Array Platform Products, subject to the remedy provisions of Section 8.2 with
respect to infringement.

       12.3 BASIS FOR TERMINATION BY LICENSEE. Licensee shall have the right,
without further obligation or liability to Agilent, to terminate this Agreement
immediately upon giving of written notice to Agilent if: (i) Agilent commits any
material breach of this Agreement and fails to remedy such breach within thirty
(30) days after receipt of written notice from Licensee of such breach, or (ii)
a Force Majeure event occurs that prevents either Party from performing any of
its material obligations hereunder and such event continues for at least thirty
(30) consecutive calendar days. Notwithstanding anything to the contrary in this
Agreement, all of Licensee's rights and remedies under this Agreement, including
but not limited to those under Sections 6, 7 and 8, shall automatically expire
upon Licensee's termination of this Agreement.

       12.4 DISPOSITION OF LICENSED ITEMS ON TERMINATION. Upon the early
termination of this Agreement for any reason, and if Licensee has not fully paid
for the Array Platform Products as specified in Exhibit A, the licenses and all
other rights granted to Licensee hereunder shall immediately cease, and Licensee
shall immediately: (i) return all LP-2's and MR-2's together with all
reproductions, modifications and Systems Upgrades of the LP-2's and MR-2's and
all copies of any documentation, notes and other materials respecting the LP-2
and MR-2; and (ii) provide Agilent with a written certification that Licensee
has complied with all of its obligations under this Section. Agilent's
termination of this Agreement and/or repossession of the LP-2's and MR-2's and
related documentation shall be without prejudice to any other remedies that
Agilent may have under this Agreement, at law or in equity.

       12.5 In the event that Agilent elects to terminate this Agreement early,
Licensee will, unless it or Agilent is otherwise prohibited by law, be afforded
a reasonable wind-down period in order to complete unfinished work before which
time the items listed in Section 12.4 shall be mandated for return and all other
rights and grants to Licensee cease in accordance with that Section 12.4.

                                       20
<PAGE>   25

13. MISCELLANEOUS.

       13.1 WAIVER, AMENDMENT OR MODIFICATION. The waiver, amendment or
modification of any provision of this Agreement or any right, power or remedy
hereunder shall not be effective unless made in writing and signed by the Party
against whom enforcement of such waiver, amendment or modification is sought.
The terms of this Agreement shall not be added to, amended or modified by the
terms of any purchase order, acknowledgement, or other form except for those
orders issued by Licensee and accepted in writing by Agilent pursuant to Section
2 hereof. No failure or delay by either Party in exercising any right, power or
remedy with respect to any of its rights hereunder shall operate as a waiver
thereof.

       13.2 NOTICE. All notices, demands or consents required or permitted under
this Agreement shall be in writing and may be delivered in person, or via
reputable overnight courier service, via confirmed facsimile transmission, or
via certified or registered mail, with postage prepaid. Notices shall be
effective when received, and shall be sent to the Parties at the following
addresses:

                    LICENSEE: DIADEXUS INC.
                              3303 Octavius Drive,
                              Santa Clara, CA 95054
                              Attn.: Mohan Iyer
                              VP Business Development
                              408-330-5031
                              miyer@diadexus.com

                    AGILENT:  AGILENT TECHNOLOGIES, INC.
                              395 Page Mill Road
                              Palo Alto, CA 94306
                              Attn.: David Hildebrandt,
                              BSP Finance

                              Copy to:
                              AGILENT TECHNOLOGIES, INC.
                              395 Page Mill Road
                              Palo Alto, CA 94306
                              Attn.: Legal Department
                                     Counsel for CAG

Each Party may change its address for notices by written notice given to the
other Party in accordance with the terms of this Section.

                                       21
<PAGE>   26

       13.3 ENTIRE AGREEMENT. This Agreement, together with the exhibits
attached hereto and with any orders issued by Licensee and accepted in writing
by Agilent pursuant to Section 1 hereof, constitutes the entire agreement
between the Parties in connection with the subject matter hereof and supersedes
all prior and contemporaneous agreements, understandings, negotiations and
discussions, whether oral or written, of the Parties, and there are no
warranties, representations and/or agreements between the Parties in connection
with the subject matter hereof except as specifically set forth or referred to
herein.

       13.4 SUCCESSORS AND ASSIGNS. All the terms and provisions of this
Agreement shall be binding upon and inure to the benefit of the Parties hereto,
and their permitted successors, assigns and legal representatives, provided that
Licensee may not assign this Agreement nor any right or remedy granted to it
hereunder, in whole or in part, voluntarily or by operation of law, without
Agilent's prior written consent. Any attempt by Licensee to do so without such
consent shall be void.

       13.5 GOVERNING LAW; SEVERABILITY. The validity, construction and
performance of this Agreement and the legal relations among the Parties hereto
shall be governed by and construed in accordance with the laws of the State of
New York, excluding that body of law applicable to choice of law. If any
provision of this Agreement or the application of any such provision shall be
held by a tribunal of competent jurisdiction to be unenforceable or contrary to
law, the remaining provisions of this Agreement shall continue in full force and
effect.

       13.6 COMPLIANCE WITH THE LAW. Licensee agrees that it will comply with
all foreign, federal, state and local laws and regulations applicable to the use
of the Array Platform Products.

       13.7 RELATIONSHIP OF THE PARTIES. Agilent and Licensee are each
independent contractors under this Agreement, and nothing herein shall be
construed to create a partnership, joint venture, or agency relationship between
them. Licensee shall have no authority to enter into agreements of any kind on
behalf of Agilent, and shall have no power or authority to bind or obligate
Agilent in any manner to any other Entity.

       13.8 SURVIVAL. The following Sections shall survive termination of this
Agreement: 1, 3.2, 3.3, 3.4, 3.5, 3.6, 5, 7.2, 8, 9,10 (as provided in that
Section 10), 11, 12.4, 13.

       13.9 PUBLICATION. Each Party shall have the right to disclose in general
terms to the public, through press releases, marketing materials, and otherwise,
that the two Parties have entered into a contractual relationship concerning
Microarray technology; provided, however, that the details and substantive terms
of this Agreement shall not be disclosed. Licensee shall cooperate and
participate, as

                                       22
<PAGE>   27

requested by Agilent, in such publication. The costs of such publications shall
be apportioned between Agilent and Licensee in accordance with the attached
exhibit.

       13.10 FORCE MAJEURE. Except for Licensee's payment obligations, neither
Party will be liable for any failure or delay in performance of any of its
obligations under this Agreement or under any orders issued by Licensee and
accepted in writing by Agilent pursuant to Section 1 hereof to the extent same
is due to any event beyond the reasonable control of such Party, including
without limitation, fire, flood, explosion, unavailability of utilities or raw
materials, act of the other Party or any other Entity, unavailability of
components, labor difficulties, war, riot, act of God, export control
regulation, action or failure to act of any governmental authority, laws,
regulations or judgments ("Force Majeure").

       13.11 COUNTERPARTS. This Agreement may be executed simultaneously in two
or more counterparts, each of which will be deemed an original, but all of which
together will constitute the same Agreement.

       13.12 HEADINGS. The headings of sections and paragraphs in this Agreement
and the exhibits attached hereto are inserted for ease of reference and shall
not affect or govern the interpretation hereof.

       In witness whereof, the Parties have executed this Agreement to become
effective as of the Effective Date.

AGILENT TECHNOLOGIES INC.               LICENSEE [diaDexus, Inc.]:

By:  /s/ DAVID J. HILDEBRANDT           By:     /s/ MOHAN S. IYER
---------------------------------       ----------------------------------------

     David J. Hildebrandt                       Mohan S. Iyer
---------------------------------       ----------------------------------------
        (PRINTED NAME)                             (PRINTED NAME)

Its:  Controller & Acting G.M.          Its:  V.P., Business Development
---------------------------------       ----------------------------------------
            (TITLE)                                    (TITLE)

      BIOSCIENCE PRODUCTS

                                       23Exhibit 4.5

                        TRANSATLANTIC HOLDINGS, INC.
                    2000 STOCK OPTION PLAN (THE "PLAN")

1. Purpose. The purpose of this Plan is to advance the interests of
Transatlantic Holdings, Inc. ("TRH") by providing certain key employees of
TRH and its subsidiaries, and members of the board of directors of TRH (the
"Board") upon whose judgment, initiative and efforts the successful conduct
of the business of TRH largely depends, with an additional incentive to
continue their efforts on behalf of TRH and its subsidiaries, as well as to
attract people of training, experience and ability to TRH and its
subsidiaries.

2. Administration. Except as otherwise provided herein, the Plan shall be
administered by a committee (the "Committee") of the Board to be drawn
solely from members of the Board who are not and have not been officers of
TRH or its subsidiaries. The Committee shall consist of at least two (2)
directors of TRH, each of which shall be (a) a Nonemployee Director (within
the meaning of Rule 16b-3 promulgated under the Securities Exchange Act of
1934, as amended) and (b) to the extent necessary for any stock option
granted hereunder intended to qualify as Performance Based Compensation
(within the meaning of Section 162(m)(4)(C) of the Code (as defined below)
and the regulations promulgated thereunder) to so qualify, an Outside
Director (within the meaning of Section 162(m) of the Code and the
regulations promulgated thereunder). For purposes of the preceding
sentence, if one or more members of the Committee is not, in the case of
clause (a) of the preceding sentence, a Nonemployee Director, or, in the
case of clause (b) of the preceding sentence, an Outside Director, and, in
either case, recuses himself or herself or abstains from voting with
respect to a particular action taken by the Committee, then the Committee,
with respect to that action, shall be deemed to consist only of the members
of the Committee who have not recused themselves or abstained from voting.
The Committee is authorized, subject to the provisions of the Plan, to
establish such rules and regulations as it deems necessary for the proper
administration of the Plan and to make such determinations and
interpretations and to take such action in connection with the Plan and any
stock options granted thereunder as it deems necessary or advisable. All
determinations and interpretations made by the Committee shall be binding
and conclusive on all optionees and on their legal representatives and
beneficiaries. The Committee shall have the authority, in its absolute
discretion, to determine which employees of TRH and its subsidiaries shall
receive stock options, the time when stock options shall be granted, the
terms of such options and the number of shares for which options shall be
granted. Notwithstanding anything to the contrary contained herein, the
Board may, in its sole discretion, at any time and from time to time, grant
stock options (including grants to members of the Board who are not
employees of TRH and its subsidiaries) or administer the Plan, in which
case the Board shall have all of the authority and responsibility granted
to the Committee herein.

3. Stock Subject to the Plan. Subject to adjustment as provided in Section
7 hereof, the maximum number of shares that may be issued under the Plan is
1,500,000 shares of the common stock, par value $1.00 per share (the
"Common Stock") of TRH as such shares shall exist on January 1, 2000 which
shares of Common Stock may, in the discretion of the Committee, be either
authorized but unissued shares or shares previously issued and reacquired
by TRH. Upon the expiration or termination (in whole or in part) of
unexercised options, shares of Common Stock subject thereto shall again be
available for issuance under the Plan.

4. Eligibility. Employees of TRH and its subsidiaries, and members of the
Board, shall be eligible to receive stock options under the Plan. Only
employees shall be eligible to receive stock options that are intended to
qualify as "incentive stock options" within the meaning of Section 422 of
the Internal Revenue Code of 1986, as amended (the "Code").

5. Grant of Stock Options. (a) Stock options may be granted to eligible
recipients in such number and at such times during the term of this Plan as
the Committee shall determine: provided, however, that (i) the maximum
number of shares of Common Stock as to which stock options may be granted
under this Plan to any one individual in any one year may not exceed
100,000 shares (as adjusted pursuant to the provisions of Section 7) and
(ii) options to purchase more than 250,000 shares of Common Stock set forth
in Section 3 above (as adjusted pursuant to the provisions of Section 7)
shall not be granted under this Plan to any one person.

     (b) At the time of grant, the Committee shall determine (i) whether
all or any part of a stock option granted to an eligible employee shall be
an incentive stock option and (ii) the number of shares subject to such
incentive stock option. The form of any stock option which is all or in
part an incentive stock option shall clearly indicate that such stock
option is an incentive stock option or, if applicable, the number of shares
subject to the incentive stock option. The aggregate fair market value
(determined as of the time the option is granted) of the stock with respect
to which incentive stock options are exercisable for the first time by an
eligible employee during any calendar year (under all such plans of TRH and
of any subsidiary corporation of TRH) shall not exceed $100,000.

6. Terms and Conditions of Stock Options. All stock options granted under
the Plan shall be in such form as the Committee may from time to time
determine and shall be subject to the following terms and conditions:

     (a) Option Price. The option price per share with respect to each
     stock option shall be determined by the Committee but shall not be
     less than 100% of the fair market value of the Common Stock on the
     date the stock option is granted.

     (b) Term of Option. In no event shall any stock option be exercisable
     after the expiration of 10 years from the date on which the stock
     option is granted.

     (c) Exercise of Stock Option and Payment for Shares. Except as
     provided in paragraph (e) of this Section below, the shares covered by
     each stock option may not be purchased for one year after the date on
     which the stock option is granted, but thereafter may be purchased in
     such installments as shall be determined by the Committee at the time
     the stock option is granted. Any shares not purchased on the
     applicable installment date may be purchased thereafter at any time
     prior to the final expiration of the stock option. To exercise a stock
     option, the optionee shall give written notice to TRH specifying the
     number of shares to be purchased and accompanied by payment of the
     full purchase price therefor: (i) in cash or by certified or official
     bank check, (ii) in shares of Common Stock held by the optionee for at
     least six months, valued as of the date of exercise, of the same class
     as those to be granted by exercise of the option, or (iii) in a
     combination of (i) and (ii). Notwithstanding the foregoing, at the
     sole discretion of the Committee, upon the request of the optionee,
     the Committee may permit, on such other terms and conditions as the
     Committee may determine, the deferral of delivery to a date or dates
     specified by the optionee of all or some of the shares otherwise
     deliverable by TRH to the optionee upon the exercise of the option.
     The Common Stock will be valued on the date of exercise at the fair
     market value as determined by the Committee. Any person exercising a
     stock option shall make such representations and agreements and
     furnish such information as the Committee may in its discretion deem
     necessary or desirable to assure compliance by TRH, on terms
     acceptable to TRH, with the provisions of the Securities Act of 1933,
     as amended, and any other applicable legal requirements. If an
     optionee so requests, shares purchased may be issued in the name of
     the optionee and another jointly with the right of survivorship.

     (d) Non-transferability of Options. No stock option granted under the
     Plan shall be transferable by the optionee other than by will or the
     laws of descent and distribution, and such stock option shall be
     exercisable, during his or her lifetime, only by the optionee.

     (e) Termination of Employment. Except as otherwise provided by the
     Committee, no part of any stock option granted to an employee
     (including an officer) may be exercised after the termination of his
     or her employment with TRH and its subsidiaries, except that (i) if
     such termination of employment is at or after normal retirement age or
     due to disability or death, any portion of a stock option, whether or
     not exercisable at the time of such termination, may be exercised by
     the optionee (or in case of death by the person or persons to whom the
     optionee's rights under such stock option are transferred by will or
     the laws of descent and distribution) at any time within the term of
     the stock option; and (ii) if such termination of employment is not at
     or after normal retirement age or due to disability or death, with the
     approval of the Committee, any portion of a stock option may be
     exercised by the optionee within three months after such termination,
     but only to the extent such stock option was exercisable at the time
     of such termination.

7. Adjustment in Event of Changes in Capitalization. In the event of a
recapitalization, stock split, stock dividend, combination or exchange of
shares, merger, consolidation, rights offering, separation, spinoff,
extraordinary dividend, reorganization or liquidation, or any other change
in the corporate structure or shares of TRH, subsequent to January 1, 2000,
the Committee shall make such equitable adjustments, designed to protect
dilution or enlargement of rights, as it may deem appropriate, in the
number and kind of shares authorized by the Plan, in the limitations set
forth in Section 5(a) and, with respect to outstanding stock options, in
the number and kind of shares covered thereby and in the option price.

8. Rights as a Stockholder. An optionee shall have no rights as a
stockholder with respect to any shares covered by a stock option until the
date of issuance of a stock certificate for such shares.

9. Withholding Taxes. Whenever shares of Common Stock are to be issued in
satisfaction of stock options granted under the Plan, TRH shall have the
right to require the recipient to remit to TRH an amount sufficient to
satisfy all applicable withholding tax requirements prior to the delivery
of any certificate or certificates for shares.

10. Term of Plan. No stock options shall be granted pursuant to the Plan
after December 31, 2009 but stock options theretofore granted may extend
beyond such date and the terms and conditions of the Plan shall continue to
apply thereto.

11. Choice of Law. THIS PLAN SHALL BE GOVERNED BY AND CONSTRUED IN
ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO
PRINCIPLES OF CONFLICT OF LAWS.

12. Termination or Amendment of Plan. The Board may at any time terminate
the Plan with respect to any shares of Common Stock of TRH not at the time
subject to option, and may from time to time alter or amend the Plan or any
part thereof, provided that no change may be made in any stock option
theretofore granted which would impair the rights of an optionee without
the consent of such optionee, and further, that no alteration or amendment
may be made without the approval of stockholders if such approval is
required by applicable law.

13. Approval of Stockholders. The Plan is being adopted as of January 1,
2000 by the Board subject to approval by the stockholders of TRH at the
2000 Annual Meeting of Stockholders. Any stock options granted under the
Plan prior to the date of such stockholder approval are expressly
conditioned on such stockholder approval.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00018-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00018-of-00352.parquet"}]]